GAN & LEE PHARMACEUTICAL
甘李药业山东有限公司办公室地址位于 山东省临沂市经济开发区朝阳街道长安路88号，于2019年10月25日在工商局注册成立，注册资本为5000(万元)，在公司发展壮大的3年里，我们始终为客户提供好的产品、良好的技术支持、健全的售后服务，我公司主要经营生物药品制造；化学药品原料药制造；化学药品制剂制造；西药批发；医疗用品及器材批发；药品零售；医疗用品及器材零售；研制生物制品、生物原料药、小容量重组产品注射剂；批发医疗器械Ⅲ类；开发生物制品；销售自产产品；货物专用运输；批发医疗器械Ⅱ类；批发和零售医疗器械；药品生产，药品的技术开发、技术转让、技术服务，货物或技术进出口。 ，我们始终为客户提供好的产品和服务，我公司所属行业为药品包装机械公司，如果您对我公司的产品服务有兴趣，期待您在线留言或者来电咨询
Country/Area ：China
Company Email ：info@ganlee.com
Industry ：制造业/医药制造业Health & MedicalManufacturing GeneralManufacturingPackaging & PrintingMachinery
Company address ：通州区漷 8 县, Beijing, China
Company website ：*****
Company phone ：+86 1056965000
Established ：1998
Company Revenue ：$8,291,000
Number of employees ：35
SIC Code ：28283
NAICS Code ：54541
Main Products ：Patients and HCPS2024-07-11 Gan & Lee Pharmaceuticals Announces Received Approval of Local-filling Insulin Aspart 30 Injection in Bangladesh京ICP备10213074号-1 |2024-06-22 Gan & Lee Pharmaceuticals Announces Significant Progress on New Diabetes and Obesity Treatments at the American Diabetes Association's 84th Scientific Sessions2024-06-18 Gan & Lee Pharmaceuticals to Present Groundbreaking Data on Three Innovative Products at the American Diabetes Association's 84th Scientific SessionsMedical DevicesBusiness Development2024-07-22 Gan & Lee Pharmaceuticals’ Bi-weekly（twice a month） GLP-1 Receptor Agonist GZR18 Injection Achieved 17.29% Weight Loss at 30 Weeks in a Phase IIb Clinical Trial2024-07-11 Gan & Lee Pharmaceuticals Successfully Shines at the American Diabetes Association's 84th Scientific Sessions2024-06-25 Gan & Lee Pharmaceuticals Shines at the 22nd CPHI China
Company News
Gan & Lee Pharmaceuticals Begins First-In-Human Trial in U.S. for Investigational Drug, GZR18
Mar 10, 2022
BEIJING and BRIDGEWATER, N.J., March 10, 2022 /PRNewswire/ -- Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee, stock code: 603087.SH), is pleased to announce the first subject has been dosed in our Phase I, double-blinded, randomized, placebo-controlled,...
Mar 10, 2022
Gan & Lee Pharmaceuticals Concludes Phase 3 Studies of Gan & Lee Insulin Glargine (GL-GLA)Oct 14, 2021
BEIJING and BRIDGEWATER, N.J., Oct. 14, 2021 /PRNewswire/ -- Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee) (Shanghai: 603087.SH), is pleased to announce the completion of two randomized, multicenter, phase 3 studies that compare proposed biosimilar Gan & Lee...
Oct 14, 2021Gan & Lee Pharmaceuticals to present data at the 57th Annual European Association for the Study of Diabetes MeetingSep 9, 2021
BEIJING and BRIDGEWATER, N. J., Sept. 9, 2021 /PRNewswire/ -- Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee, stock code: 603087.SH), is excited to present positive data from five abstracts which will be featured as short oral discussions at the 57th Annual...
Sep 9, 2021New Data on Phase 1 Proposed Biosimilar Gan & Lee Insulins Aspart (GL-ASP), Lispro (GL-LIS), and Glargine (GL-GLA) Presented at the American Diabetes Association's 81st Scientific SessionsJul 2, 2021
BEIJING and BRIDGEWATER, NJ., July 2, 2021 /PRNewswire/ -- Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee, stock code: 603087.SH), announced positive Phase 1 clinical trial results at the 81st Scientific Sessions of the American Diabetes Association (ADA), June...
Jul 2, 2021Gan & Lee receives EMA orphan drug designation for Phase I drug candidate GLR2007 for the treatment of gliomaApr 6, 2021
BEIJING and BRIDGEWATER, N.J., April 6, 2021 /PRNewswire/ -- Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee, stock code: 603087.SH), a global biopharmaceutical company, today announced that the European Medicine Agency (EMA) Committee for Orphan Medicinal...
Apr 6, 2021Web Summary
The text appears to be a company profile for Gan & Lee Pharmaceuticals, a Chinese pharmaceutical company with subsidiaries and offices in various countries around the world.
Here are some key points that can be extracted from the text:
1. Company History: The company was founded in 1998 in Beijing, China.
2. Subsidiaries: The company has several subsidiaries, including Gan & Lee Pharmaceuticals Shandong Co., Ltd., Gangan Technology Co., Ltd., and Gangan Medical Technology Jiangsu Co., Ltd., among others.
3. Business Segments: The company's business segments include:
* Medicinal products and medical devices
* Chemical production base
* International business development
4. Products: The company develops and manufactures various products, including pen-type insulin syringes, blood glucose meters, and pre-filled pens.
5. Geographic Presence: The company has offices and subsidiaries in China, Hong Kong, the United States, Germany, and other countries.
6. Business Development: The company is involved in international business development, clinical trials, registration, and business development.
Overall, Gan & Lee Pharmaceuticals appears to be a diversified pharmaceutical company with a strong presence in Asia and globally.
Here are some key points that can be extracted from the text:
1. Company History: The company was founded in 1998 in Beijing, China.
2. Subsidiaries: The company has several subsidiaries, including Gan & Lee Pharmaceuticals Shandong Co., Ltd., Gangan Technology Co., Ltd., and Gangan Medical Technology Jiangsu Co., Ltd., among others.
3. Business Segments: The company's business segments include:
* Medicinal products and medical devices
* Chemical production base
* International business development
4. Products: The company develops and manufactures various products, including pen-type insulin syringes, blood glucose meters, and pre-filled pens.
5. Geographic Presence: The company has offices and subsidiaries in China, Hong Kong, the United States, Germany, and other countries.
6. Business Development: The company is involved in international business development, clinical trials, registration, and business development.
Overall, Gan & Lee Pharmaceuticals appears to be a diversified pharmaceutical company with a strong presence in Asia and globally.
Customs Data
As a purchaser
As a Supplier
Get the Whole details
Contact
Total found ??? Contacts
All
Boss
Management
Procurement
Other
Get the Whole details
